Supplementing Consent for a Prospective Longitudinal Cohort Study of Infants With Antenatal Opioid Exposure:

Jamie E Newman1, Leslie Clarke2, Pranav Athimuthu1

  • 1RTI International, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, United States, 1 9194855719.

PubMed

Insights

A digital consenter video improved understanding of the Outcomes of Babies With Opioid Exposure (OBOE) study, aiding informed consent. This tool increased enrollment, especially for opioid-exposed infants and caregivers who selected matching avatars.

Area of Science:

  • Medical research methodology
  • Digital health tools
  • Patient engagement

Background:

  • The Outcomes of Babies With Opioid Exposure (OBOE) study faced recruitment challenges due to COVID-19 restrictions impacting in-person consent discussions.
  • A digital consenter video tool was developed to enhance engagement and understanding of study procedures for potential participants.

Purpose of the Study:

  • To evaluate participant knowledge of the OBOE study after viewing the digital tool.
  • To assess participant experiences with the informed consent process using the video.
  • To gauge perceptions of the consenter video among potential study participants.

Main Methods:

  • 129 caregivers were offered a supplementary consenter video featuring diverse avatars.
  • Participants completed a survey on study knowledge, consent experience, and tool perception.
  • Chi-square tests analyzed differences between opioid-exposed and unexposed infant caregivers, and the impact of avatar selection on enrollment.

Main Results:

  • High participant understanding of study purpose (95%) and MRI procedures (88%) was observed.
  • Nearly all participants felt they received adequate information (98%) and understood it well (97%).
  • Caregivers of opioid-exposed infants were more likely to enroll (89% vs. 51%).
  • Matching avatar selection correlated with higher enrollment rates (83% vs. 57%).

Conclusions:

  • The interactive digital consenter tool effectively informed prospective participants.
  • The tool improved the informed consent process and clarified study rationale, particularly for control group families.
  • The resource aided understanding of magnetic resonance imaging (MRI) procedures.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...